Kaken Pharmaceutical Co (TSE:4521) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Debt-to-Equity?

Kaken Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円3,850 Mil. Kaken Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Kaken Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円140,135 Mil. Kaken Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kaken Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

TSE:4521' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.03 Max: 0.07
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Kaken Pharmaceutical Co was 0.07. The lowest was 0.03. And the median was 0.03.

TSE:4521's Debt-to-Equity is ranked better than
89.25% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSE:4521: 0.03

Kaken Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Kaken Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Debt-to-Equity Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

Kaken Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Competitive Comparison of Kaken Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaken Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Debt-to-Equity falls into.

Kaken Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kaken Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3850	+	0)	/	136257
	=	0.03

Kaken Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3850	+	0)	/	140135
	=	0.03

Kaken Pharmaceutical Co (TSE:4521) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kaken Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines